Clinical evaluation of the vasodilator MDL-899 in patients with essential hypertension.

Abstract

In this study of 10 patients with essential hypertension inadequately controlled by standard beta-blocker-diuretic combination therapy, the addition of 5 mg of MDL-899, a peripheral arteriolar vasodilator, resulted in significant reductions in blood pressure, both supine and standing, which was maximal 4-8 h after dosing, with no additional orthostatic component. There were associated small rises in heart rate but no evidence of significant activation of the sympathetic or renin-angiotensin systems. Six patients continued for 4 weeks receiving MDL-899 twice daily with significant improvement in their blood pressure control--from a mean of 182/95 to 146/77 mm Hg (supine) and from 161/93 to 138/79 mm Hg (erect). These six patients experienced no significant side effects, but four patients were unable to proceed with the study as a result of adverse effects, particularly headache, following the first few doses. It seems likely that these side effects are dose related. In a combined drug regimen, MDL-899 is an effective vasodilator drug that significantly improved the blood pressure control of patients with essential hypertension.

• Authors: H L Elliott, L Campbell, D J Sumner, J L Reid
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) 1985 Sep-Oct Vol. 7 Issue 5 Pg. 948-52 ISSN: 0160-2446 [Print] United States
• PMID: 2413306 (Publication Type: Journal Article)

Chemical References

• Pyridazines
• Vasodilator Agents
• Aldosterone
• mopidralazine
• Renin

Topics

• Aged
• Aldosterone (blood)
• Blood Pressure (drug effects)
• Female
• Heart Rate (drug effects)
• Humans
• Hypertension (drug therapy, physiopathology)
• Male
• Middle Aged
• Pyridazines (adverse effects, therapeutic use)
• Renin (blood)
• Time Factors
• Vasodilator Agents (adverse effects, therapeutic use)